Market News

As Travelers Companies (TRV) Market Valuation Rose, Shareholder Federated Investors Has Cut by $37.82 Million Its Stake; Dorsey Wright & Associates Decreased Bio Rad Labs Cl A (BIO) Position by $1.79 Million

Bio-Rad Laboratories, Inc. (NYSE:BIO) Logo

Dorsey Wright & Associates decreased its stake in Bio Rad Labs Inc Cl A (BIO) by 47.61% based on its latest 2017Q4 regulatory filing with the SEC. Dorsey Wright & Associates sold 7,514 shares as the company’s stock rose 2.21% while stock markets declined. The institutional investor held 8,269 shares of the capital goods company at the end of 2017Q4, valued at $1.97M, down from 15,783 at the end of the previous reported quarter. Dorsey Wright & Associates who had been investing in Bio Rad Labs Inc Cl A for a number of months, seems to be less bullish one the $8.50 billion market cap company. The stock decreased 1.68% or $4.89 during the last trading session, reaching $286.82. About 391,342 shares traded or 139.06% up from the average. Bio-Rad Laboratories, Inc. (NYSE:BIO) has risen 25.02% since May 18, 2017 and is uptrending. It has outperformed by 13.47% the S&P500.

Federated Investors Inc decreased its stake in Travelers Companies Inc (TRV) by 50.63% based on its latest 2017Q4 regulatory filing with the SEC. Federated Investors Inc sold 280,150 shares as the company’s stock rose 1.76% while stock markets declined. The institutional investor held 273,146 shares of the finance company at the end of 2017Q4, valued at $37.05 million, down from 553,296 at the end of the previous reported quarter. Federated Investors Inc who had been investing in Travelers Companies Inc for a number of months, seems to be less bullish one the $35.33B market cap company. The stock increased 0.44% or $0.57 during the last trading session, reaching $130.72. About 807,806 shares traded. The Travelers Companies, Inc. (NYSE:TRV) has risen 13.01% since May 18, 2017 and is uptrending. It has outperformed by 1.46% the S&P500.

More notable recent Bio-Rad Laboratories, Inc. (NYSE:BIO) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: FDA Panel Nod For Akcea, Synergy’s Revenue Miss, FDA Warns E-Liquid Makers Again” on May 11, 2018, also Businesswire.com with their article: “Bio-Rad Reports First Quarter 2018 Financial Results” published on May 08, 2018, Benzinga.com published: “Benzinga’s Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer’s Trial …” on May 10, 2018. More interesting news about Bio-Rad Laboratories, Inc. (NYSE:BIO) were released by: Benzinga.com and their article: “Benzinga’s Daily Biotech Pulse: Aytu Rallies On Earnings, Evolus Awaits FDA Verdict, BofA Conference Underway” published on May 15, 2018 as well as Benzinga.com‘s news article titled: “Benzinga’s Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More” with publication date: May 17, 2018.

Since December 14, 2017, it had 0 insider buys, and 1 insider sale for $1.24 million activity.

Analysts await Bio-Rad Laboratories, Inc. (NYSE:BIO) to report earnings on August, 2. They expect $1.25 EPS, up 115.52% or $0.67 from last year’s $0.58 per share. BIO’s profit will be $37.04 million for 57.36 P/E if the $1.25 EPS becomes a reality. After $1.17 actual EPS reported by Bio-Rad Laboratories, Inc. for the previous quarter, Wall Street now forecasts 6.84% EPS growth.

Among 5 analysts covering Bio-Rad Laboratories (NYSE:BIO), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Bio-Rad Laboratories had 20 analyst reports since August 7, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Friday, November 3 by Jefferies. The company was upgraded on Wednesday, June 28 by Deutsche Bank. The stock of Bio-Rad Laboratories, Inc. (NYSE:BIO) has “Buy” rating given on Friday, April 28 by Jefferies. On Thursday, June 8 the stock rating was maintained by Jefferies with “Buy”. The firm has “Buy” rating by Jefferies given on Wednesday, September 27. On Wednesday, September 7 the stock rating was maintained by Jefferies with “Buy”. On Friday, October 20 the stock rating was maintained by Jefferies with “Buy”. Jefferies maintained it with “Buy” rating and $250 target in Wednesday, April 12 report. The stock has “Neutral” rating by CL King on Friday, February 16. The firm has “Hold” rating given on Friday, February 16 by C.L. King.

Investors sentiment increased to 1.13 in 2017 Q4. Its up 0.35, from 0.78 in 2017Q3. It is positive, as 23 investors sold BIO shares while 89 reduced holdings. 44 funds opened positions while 82 raised stakes. 18.57 million shares or 0.31% more from 18.51 million shares in 2017Q3 were reported. Oppenheimer Asset invested 0.01% of its portfolio in Bio-Rad Laboratories, Inc. (NYSE:BIO). Synovus Corporation reported 0% in Bio-Rad Laboratories, Inc. (NYSE:BIO). Portolan Mngmt Ltd holds 1.81% in Bio-Rad Laboratories, Inc. (NYSE:BIO) or 69,080 shares. Moreover, State Treasurer State Of Michigan has 0.01% invested in Bio-Rad Laboratories, Inc. (NYSE:BIO) for 7,300 shares. Quantitative Systematic Strategies Limited Com holds 4,587 shares. Trexquant Invest Limited Partnership invested 0.03% of its portfolio in Bio-Rad Laboratories, Inc. (NYSE:BIO). 13,664 are held by Texas Permanent School Fund. 9,959 are owned by Mason Street Advisors Lc. Bridgewater Assoc Lp has 19,255 shares. D E Shaw Inc reported 0.04% of its portfolio in Bio-Rad Laboratories, Inc. (NYSE:BIO). Jpmorgan Chase, a New York-based fund reported 44,599 shares. Deutsche Bankshares Ag, a Germany-based fund reported 92,030 shares. 1,800 were reported by Art Advsrs Ltd Liability Corporation. Gsa Cap Prns Llp invested in 3,872 shares or 0.06% of the stock. Dorsey Wright And Associates holds 0.36% or 8,269 shares.

Dorsey Wright & Associates, which manages about $743.59M and $553.36 million US Long portfolio, upped its stake in United Rentals Inc Com (NYSE:URI) by 5,450 shares to 39,126 shares, valued at $6.73 million in 2017Q4, according to the filing. It also increased its holding in Stora Enso Corp Spon Adr Rep R (SEOAY) by 127,875 shares in the quarter, for a total of 473,468 shares, and has risen its stake in Sap Se Spon Adr (NYSE:SAP).

Analysts await The Travelers Companies, Inc. (NYSE:TRV) to report earnings on July, 19. They expect $2.43 earnings per share, up 26.56% or $0.51 from last year’s $1.92 per share. TRV’s profit will be $656.74M for 13.45 P/E if the $2.43 EPS becomes a reality. After $2.46 actual earnings per share reported by The Travelers Companies, Inc. for the previous quarter, Wall Street now forecasts -1.22% negative EPS growth.

Among 17 analysts covering Travelers (NYSE:TRV), 6 have Buy rating, 2 Sell and 9 Hold. Therefore 35% are positive. Travelers had 60 analyst reports since July 22, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Monday, June 19 by Keefe Bruyette & Woods. The stock has “Outperform” rating by RBC Capital Markets on Wednesday, July 22. The firm has “Buy” rating given on Friday, October 20 by Citigroup. The firm earned “Underweight” rating on Friday, October 20 by Morgan Stanley. The rating was downgraded by FBR Capital to “Mkt Perform” on Monday, February 13. The firm has “Neutral” rating by Citigroup given on Wednesday, October 21. Macquarie Research upgraded the stock to “Outperform” rating in Tuesday, January 17 report. On Tuesday, January 10 the stock rating was downgraded by Goldman Sachs to “Sell”. The stock of The Travelers Companies, Inc. (NYSE:TRV) has “Buy” rating given on Monday, October 2 by Citigroup. Argus Research maintained the stock with “Buy” rating in Thursday, April 26 report.

Bio-Rad Laboratories, Inc. (NYSE:BIO) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *